Table 1 19q12 amplification in 313 breast cancers and clinicopathological associations
From: Functional characterization of the 19q12 amplicon in grade III breast cancers
|
19q12 Amp n (%) |
19q12 Not amp n (%) | P-value |
CCNE1
Amp (%) |
CCNE1
Not amp (%) | P-value | ||
|---|---|---|---|---|---|---|---|
| Whole cohort | 16 (5.1%) | 297 (94.9%) | NA | 5 (1.6%) | 308 (98.4%) | NA | |
| Histological grade* | 0.0018 + | 0.1693+ | |||||
| I/II | 0 (0%) | 109 (100%) | 0 (0%) | 109 (100%) | |||
| III | 16 (8%) | 188 (92%) | 5 (2%) | 199 (98%) | |||
| ER | 0.0042 + | 0.01984 + | |||||
| Positive | 3 (2%) | 166 (98%) | 0 (0%) | 169 (100%) | |||
| Negative | 13 (9%) | 131 (91%) | 5 (3.5%) | 139 (96.5%) | |||
| HER2 | 0.5398+ | 0.9801+ | |||||
| Positive | 2 (3%) | 62 (97%) | 1(1.6%) | 63(98.4%) | |||
| Negative | 14 (6%) | 235 (94%) | 4(1.6%) | 245(98.4%) | |||
| Subtypes | 0.0056**^ | 0.0500**^ | |||||
| ER-/HER2- | 11 (11%) | 90 (89%) | 0.0024*** | 4 (4%) | 97 (96%) | 0.0399*** | |
| HER2 | 2 (3%) | 62 (97%) | 1 (2%) | 63 (98%) | |||
| ER+/HER2- | 3 (2%) | 145 (98%) | 0 (0%) | 148 (100%) |
